X-ZELL cancer detection technology on show at Phar-East 2020
Singapore, February 2020 – X-ZELL has been selected as one of 50 start-ups to be featured at the upcoming Phar-East Summit in Singapore.
To be held between 30 June and 1 July at the Resorts World Convention Centre on Sentosa – an island just off Singapore’s southern coast – Phar-East 2020 is an innovation and technology festival focusing on the region’s burgeoning biotech and pharma community.
Organised by Sydney-based event company, Terrapinn, Phar-East is expected to attract more than 1,000 visitors in 2020, with more than 100 high-profile speakers confirmed across six areas of interest – Immunotherapy, Clinical Trials, Pharma 4.0, Market Access & Pricing, Bio Data and Biotech Invest.
In a first for the Summit, the 2020 edition will also feature a dedicated Start-Up Innovation Zone featuring 50 of the industry’s most promising newcomers – including Singapore’s own X-ZELL.
Dedicated pitch sessions will be held on both days of the event as part of the Biotech Invest track, with time slots yet to be confirmed.
Ranked among Asia’s 50 most innovative health tech start-ups for two years running, X-ZELL is fusing next-generation cell detection technology with cutting-edge AI to detect early-stage cancers in a small, 10mL blood sample.
UPDATED (15 MAY 2020):
Due to the disruption caused by the coronavirus across the region, the restrictions being placed on international travel and after consultation with the industry, Terrapinn has taken the decision to postpone Phar-East 2020. The event was due to take place between 31 Mar – 1 Apr and will now be held between 8-9 Dec.
Date: 8 – 9 Dec 2019
Venue: Resorts World Convention Centre, Sentosa, Singapore
Head of Strategy, Marketing & Communications
+65 9630 0706
Recurrently ranked among the most innovative health technology start-ups in Asia, X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines when it demonstrated the ability to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in small, 10mL blood samples. Widely considered one of the most promising biomarkers for the early detection of clinically significant cancers, tCEC had previously been classified as undetectable in clinical routine. Now headquartered in Singapore, X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.
About Phar-East 2020
First held in 2008 as BioMedical Asia, Phar-East is the result of 2018 rebranding exercise undertaken to reflect the changing nature of Singapore’s vibrant entrepreneurial and technology innovation ecosystem. Since then, the event has established itself as an international platform bringing together big pharma and biotech, regulators and payers, solution providers and technology leaders to build new relationships, cement existing partnerships and chart the path forward in Asia’s life sciences industry.